RECRUITINGINTERVENTIONAL

Impact of Capillaroscopy in the Investigation of Diffuse Interstitial Pneumonias

About This Trial

The investigators hypothesize that in patients with a new diagnosis of Pulmonary Interstitial Disease (PID), adding capillaroscopy to standard care increases the proportion of patients receiving a diagnosis of PID-Connective Tissue Disease (PID-CTD) within the first three months of follow-up, thereby reducing the time to diagnosis and facilitating the implementation of appropriate treatment as quickly as possible. Therefore, To confirm this hypothesis, it is necessary to know the characteristics of capillaroscopy in patients with a new diagnosis of PID.

Who May Be Eligible (Plain English)

Who May Qualify: - Male or female over 18 years of age; - Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist; - Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity measurement, immunological assessment including: screening for FAN, FR, and anti-CCP); - French-speaking patient with no comprehension difficulties; - Person affiliated with or beneficiary of a social security system; - Free, informed, and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research). Who Should NOT Join This Trial: - Have previously undergone a capillaroscopy, regardless of the reason; - Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation; - Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic therapy; - Pregnant or breastfeeding women; - Patients covered by Articles L 1121-5 to L 1121-8 (persons deprived of their liberty by judicial or administrative decision, minors, adults subject to legal protection measures, or persons unable to give their consent). Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Male or female over 18 years of age; * Have received a new diagnosis of PID within the last six months, confirmed by a pulmonologist; * Have undergone some specific tests within the last six months (Chest CT scan, respiratory function tests (plethysmography and CO transfer capacity measurement, immunological assessment including: screening for FAN, FR, and anti-CCP); * French-speaking patient with no comprehension difficulties; * Person affiliated with or beneficiary of a social security system; * Free, informed, and written consent signed by the participant and the investigator (no later than the day of inclusion and before any examination required by the research). Exclusion Criteria: * Have previously undergone a capillaroscopy, regardless of the reason; * Have a diagnosis or high suspicion of connective tissue disease based on initial clinical and paraclinical evaluation; * Have already started one of the following treatments for pulmonary involvement: systemic corticosteroids, immunosuppressive therapy, antifibrotic therapy; * Pregnant or breastfeeding women; * Patients covered by Articles L 1121-5 to L 1121-8 (persons deprived of their liberty by judicial or administrative decision, minors, adults subject to legal protection measures, or persons unable to give their consent).

Treatments Being Tested

DIAGNOSTIC_TEST

capillaroscopy

Capillaroscopy will be performed during a specific consultation. During this examination, a device called a "video capillaroscope" is used to magnify and visualize the capillaries located at the base of the nail. The examination lasts approximately twenty minutes.

Locations (1)

CHU de Bordeaux - service de rhumatologie

Bordeaux, France